diethylcarbamazine

Trade name: hetrazan

Small moleculeapproved

Approved

Nov 13, 1950

Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India. — NCATS

Clinical trial activity

17 trials · 21 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2001 (NCT00295698)

Timeline

1950s

Nov 13, 1950
Lederle — Earliest FDA Approval
Nov 13, 1950
Lederle — NDA Organization
Nov 13, 1950
American Cyanamid — NDA Secondary Org

2000s

Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Jan 1, 2007
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2018
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Nematode GABA-A receptorPOSITIVE MODULATOR
Nematode GABA-A receptor positive modulator
- Uncharacterized protein ↗
- Uncharacterized protein ↗

Approval history

approvedNov 13, 1950

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)C(=O)N1CCN(C)CC1

Mol. weight: 199.3 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Discontinued

Oral

Yes

Parenteral

Topical

Sources

Also known as

banocide
banocide
bitirazine
camin
camin
carbilazine
caricide
decacide
decacide
diethylcarbamazin
diethylcarbamazin
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diethylcarbamazine
diéthylcarbamazine
diéthylcarbamazine
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazine citrate
diethylcarbamazinum
diethylcarbamazinum
dietilcarbamazina
dietilcarbamazina
difil
dirocide
dirocide
ethodryl
filarabits
filarabits
hetrazan
hetrazan
hetrazan
nemacide
nemacide
n,n-diethyl-4-methyl-1-piperazinecarboxamide
n,n-diethyl-4-methyl-1-piperazinecarboxamide
notezine
timox

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07159373	Phase 3	Mar 31, 2026	Medicines Development for Global Health, Murdoch University, University of New South Wales
NCT06070116	Phase 2	Jan 15, 2024	Washington University in St. Louis
NCT04410406	Phase 3	Jul 1, 2020	Case Western Reserve University, Regional Hospital of Agboville, Southern Cote d'Ivoire, Washington University in St. Louis
NCT04188301	Phase 2	Dec 31, 2019	Case Western Reserve University, University of Health and Allied Sciences, Ghana, Washington University in St. Louis
NCT03676140	Phase 3	Oct 31, 2018	Government of Papua New Guinea, Lihir Medical Centre, University of London
NCT03664063	Phase 2	Sep 30, 2018	Lihir Medical Centre
NCT03177993	N/A	Jul 10, 2017	Case Western Reserve University, Murdoch University, The Task Force for Global Health, Washington University in St. Louis
NCT02899936	N/A	Jul 1, 2016	Case Western Reserve University, Indian Council of Medical Research, Washington University in St. Louis
NCT02974049	N/A	Jan 1, 2015	Case Western Reserve University, Washington University in St. Louis
NCT01975441	Phase 2	May 1, 2014	Case Western Reserve University, Papua New Guinea Institute of Medical Research
NCT01593722	Phase 4	Apr 1, 2012	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01111305	Phase 2	Apr 1, 2010	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02005653	Phase 4	Feb 1, 2009	Indian Council of Medical Research
NCT00511004	Phase 2	Jul 1, 2007	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00849797	Phase 1	Jul 1, 2005	SFBC Anapharm, Teva
NCT00850174	Phase 1	Apr 1, 2005	Pharma Medica, Teva
NCT00295698	N/A	Aug 1, 2001	Danish Council for Development Research, The AIDS Foundation, Denmark, The Wedell-Wedellsborg Foundation, Denmark, University of Copenhagen

Showing 17 of 17 trials

Page 1 / 1

Organizations

Research & Development (21)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Case Western Reserve University	Academic/Hospital	6	2	3	2014
Washington University in St. Louis	Academic/Hospital	6	5	3	2015
National Institute of Allergy and Infectious Diseases (NIAID)	Government	3	3	2	2007
Indian Council of Medical Research	Academic/Hospital	2	1	2	2009
Lihir Medical Centre	Academic/Hospital	2	2	2	2018
Murdoch University	Academic/Hospital	2	0	2	2017
Teva	For profit	2	2	1	2005
Danish Council for Development Research	Government	1	0	1	2001
Government of Papua New Guinea	Government	1	0	1	2018
Medicines Development for Global Health	For profit	1	1	1	2026
Papua New Guinea Institute of Medical Research	Academic/Hospital	1	0	1	2014
Pharma Medica	For profit	1	0	1	2005
Regional Hospital of Agboville, Southern Cote d'Ivoire	Academic/Hospital	1	0	1	2020
SFBC Anapharm	For profit	1	0	1	2005
The AIDS Foundation, Denmark	Academic/Hospital	1	0	1	2001
The Task Force for Global Health	Academic/Hospital	1	0	1	2017
The Wedell-Wedellsborg Foundation, Denmark	Academic/Hospital	1	0	1	2001
University of Copenhagen	Academic/Hospital	1	1	1	2001
University of Health and Allied Sciences, Ghana	Academic/Hospital	1	0	1	2019
University of London	Academic/Hospital	1	0	1	2018

21 organizations

Page 1 / 2

Marketing (2)

Organization	Org type	Relationship	Date
American Cyanamid	For profit	NDA2	Nov 13, 1950
Lederle	For profit	NDA	Nov 13, 1950